56 related articles for article (PubMed ID: 38758826)
21. Targeting the MET-Signaling Pathway in Non-Small-Cell Lung Cancer: Evidence to Date.
Bylicki O; Paleiron N; Assié JB; Chouaïd C
Onco Targets Ther; 2020; 13():5691-5706. PubMed ID: 32606781
[TBL] [Abstract][Full Text] [Related]
22. The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer.
De Mello RA; Neves NM; Amaral GA; Lippo EG; Castelo-Branco P; Pozza DH; Tajima CC; Antoniou G
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32575417
[No Abstract] [Full Text] [Related]
23. Tepotinib in Non-Small-Cell Lung Cancer with
Paik PK; Felip E; Veillon R; Sakai H; Cortot AB; Garassino MC; Mazieres J; Viteri S; Senellart H; Van Meerbeeck J; Raskin J; Reinmuth N; Conte P; Kowalski D; Cho BC; Patel JD; Horn L; Griesinger F; Han JY; Kim YC; Chang GC; Tsai CL; Yang JC; Chen YM; Smit EF; van der Wekken AJ; Kato T; Juraeva D; Stroh C; Bruns R; Straub J; Johne A; Scheele J; Heymach JV; Le X
N Engl J Med; 2020 Sep; 383(10):931-943. PubMed ID: 32469185
[TBL] [Abstract][Full Text] [Related]
24. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.
Liang H; Wang M
Onco Targets Ther; 2020; 13():2491-2510. PubMed ID: 32273721
[TBL] [Abstract][Full Text] [Related]
25. Acquired resistance to targeted therapies in NSCLC: Updates and evolving insights.
Meador CB; Hata AN
Pharmacol Ther; 2020 Jun; 210():107522. PubMed ID: 32151666
[TBL] [Abstract][Full Text] [Related]
26. MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by
Sato H; Schoenfeld AJ; Siau E; Lu YC; Tai H; Suzawa K; Kubota D; Lui AJW; Qeriqi B; Mattar M; Offin M; Sakaguchi M; Toyooka S; Drilon A; Rosen NX; Kris MG; Solit D; De Stanchina E; Davare MA; Riely GJ; Ladanyi M; Somwar R
Clin Cancer Res; 2020 Jun; 26(12):2932-2945. PubMed ID: 32122926
[TBL] [Abstract][Full Text] [Related]
27. Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLC.
Recondo G; Bahcall M; Spurr LF; Che J; Ricciuti B; Leonardi GC; Lo YC; Li YY; Lamberti G; Nguyen T; Milan MSD; Venkatraman D; Umeton R; Paweletz CP; Albayrak A; Cherniack AD; Price KS; Fairclough SR; Nishino M; Sholl LM; Oxnard GR; Jänne PA; Awad MM
Clin Cancer Res; 2020 Jun; 26(11):2615-2625. PubMed ID: 32034073
[TBL] [Abstract][Full Text] [Related]
28. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration.
Drilon A; Clark JW; Weiss J; Ou SI; Camidge DR; Solomon BJ; Otterson GA; Villaruz LC; Riely GJ; Heist RS; Awad MM; Shapiro GI; Satouchi M; Hida T; Hayashi H; Murphy DA; Wang SC; Li S; Usari T; Wilner KD; Paik PK
Nat Med; 2020 Jan; 26(1):47-51. PubMed ID: 31932802
[TBL] [Abstract][Full Text] [Related]
29. The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding.
Kubala MH; DeClerck YA
Cancer Metastasis Rev; 2019 Sep; 38(3):483-492. PubMed ID: 31734763
[TBL] [Abstract][Full Text] [Related]
30. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy.
Skoulidis F; Heymach JV
Nat Rev Cancer; 2019 Sep; 19(9):495-509. PubMed ID: 31406302
[TBL] [Abstract][Full Text] [Related]
31. Mechanochemical Signaling of the Extracellular Matrix in Epithelial-Mesenchymal Transition.
Scott LE; Weinberg SH; Lemmon CA
Front Cell Dev Biol; 2019; 7():135. PubMed ID: 31380370
[TBL] [Abstract][Full Text] [Related]
32. Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment.
Duma N; Santana-Davila R; Molina JR
Mayo Clin Proc; 2019 Aug; 94(8):1623-1640. PubMed ID: 31378236
[TBL] [Abstract][Full Text] [Related]
33. Plasminogen Activator Inhibitor 1 (PAI1) Promotes Actin Cytoskeleton Reorganization and Glycolytic Metabolism in Triple-Negative Breast Cancer.
Humphries BA; Buschhaus JM; Chen YC; Haley HR; Qyli T; Chiang B; Shen N; Rajendran S; Cutter A; Cheng YH; Chen YT; Cong J; Spinosa PC; Yoon E; Luker KE; Luker GD
Mol Cancer Res; 2019 May; 17(5):1142-1154. PubMed ID: 30718260
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin-activated PAI-1 secretion in the cancer-associated fibroblasts with paracrine effects promoting esophageal squamous cell carcinoma progression and causing chemoresistance.
Che Y; Wang J; Li Y; Lu Z; Huang J; Sun S; Mao S; Lei Y; Zang R; Sun N; He J
Cell Death Dis; 2018 Jul; 9(7):759. PubMed ID: 29988148
[TBL] [Abstract][Full Text] [Related]
35. Aberrant SERPINE1 DNA methylation is involved in carboplatin induced epithelial-mesenchymal transition in epithelial ovarian cancer.
Pan JX; Qu F; Wang FF; Xu J; Mu LS; Ye LY; Li JJ
Arch Gynecol Obstet; 2017 Dec; 296(6):1145-1152. PubMed ID: 28975405
[TBL] [Abstract][Full Text] [Related]
36. Endothelial cells promote triple-negative breast cancer cell metastasis
Zhang W; Xu J; Fang H; Tang L; Chen W; Sun Q; Zhang Q; Yang F; Sun Z; Cao L; Wang Y; Guan X
FASEB J; 2018 Jan; 32(1):276-288. PubMed ID: 28899878
[TBL] [Abstract][Full Text] [Related]
37. Role of the extracellular matrix in cancer-associated epithelial to mesenchymal transition phenomenon.
Tzanakakis G; Kavasi RM; Voudouri K; Berdiaki A; Spyridaki I; Tsatsakis A; Nikitovic D
Dev Dyn; 2018 Mar; 247(3):368-381. PubMed ID: 28758355
[TBL] [Abstract][Full Text] [Related]
38. MEK inhibitors against MET-amplified non-small cell lung cancer.
Chiba M; Togashi Y; Tomida S; Mizuuchi H; Nakamura Y; Banno E; Hayashi H; Terashima M; De Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
Int J Oncol; 2016 Dec; 49(6):2236-2244. PubMed ID: 27748834
[TBL] [Abstract][Full Text] [Related]
39. Targeting Epithelial-Mesenchymal Transition (EMT) to Overcome Drug Resistance in Cancer.
Du B; Shim JS
Molecules; 2016 Jul; 21(7):. PubMed ID: 27455225
[TBL] [Abstract][Full Text] [Related]
40. Identifying the Appropriate FISH Criteria for Defining MET Copy Number-Driven Lung Adenocarcinoma through Oncogene Overlap Analysis.
Noonan SA; Berry L; Lu X; Gao D; Barón AE; Chesnut P; Sheren J; Aisner DL; Merrick D; Doebele RC; Varella-Garcia M; Camidge DR
J Thorac Oncol; 2016 Aug; 11(8):1293-1304. PubMed ID: 27262212
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
